FDA Grants Bisantrene Rare Paediatric Disease Designation
Filed with ASX · · 3 pages · English
Earlier from Racura Oncology
- Bisantrene poster presented at French Leukaemia Conference
- Bisantrene approval in UK for supply as unlicensed medicine
- RAC cancer drug success in AML reported by French doctors
- Race executes agreement for Bisantrene clinical trial
- Race signs global distribution agreement with Durbin PLC
Later from Racura Oncology
- June 2018 Quarterly Report
- Appendix 4E & Financial Statements
- September 2018 Quarterly Report
- Race appoints Biosynergy to pursue Bisantrene licensing
- Race signs agreement for Bisantrene NPP in Israel
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology